Research progress of immune checkpoint inhibitor associated pneumonia in non-small cell lung cancer and integrated TCM and Western medicine treatment
10.3969/j.issn.1000-484X.2024.01.033
- VernacularTitle:非小细胞肺癌免疫检查点抑制剂相关性肺炎研究进展及中西医结合治疗
- Author:
Jingtao ZHANG
1
;
Zichen LIU
;
Lingyun JI
;
Fei XU
Author Information
1. 山东中医药大学中医学院,济南 250300
- Keywords:
Non-small cell lung cancer;
Immune checkpoint inhibitor associated pneumonia;
PD-1/PD-L1 inhibitors;
CTLA-4 inhibitor;
Combined treatment of traditional Chinese medicine and Western medicine
- From:
Chinese Journal of Immunology
2024;40(1):213-219
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors(ICIs)mainly including the CTL antigen 4(CTLA-4)and PD-1/PD-L1,which would offer a notable clinical benefit for non-small cell lung cancer(NSCLC)patients.By strengthening the antitumor immune re-sponse of the body,ICIs lead to immune-related adverse events(irAEs),including checkpoint inhibitor pneumitis(CIP).Although the clinical incidence of CIP is relatively low,some serious cases may prolong or terminate of immunotherapy,even life threateing.This article tries to summarize the clinical manifestations,pathological characteristics,biological mechanism,susceptible population,diagnosis and differential diagnosis,and integrated traditional Chinese and Western medicine treatment of CIP,in order to understand CIP more clearly.
